Explore our portfolio that enables healthcare providers to increase value.

With our innovations we are transforming healthcare – and lives. Dive deeper into our fascinating technologies.

We drive innovation to help humans live healthier and longer. Learn more about us as a company and employer.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers adds pathway for lung cancer to its AI-based clinical decision support software
Press release

Siemens Healthineers adds pathway for lung cancer to its AI-based clinical decision support software

HIMSS 2021, Las Vegas, August 9-13, 2021

Published on August 8, 2021

Download this press release(pdf, 182.54 KB)

Download image

(jpeg, 28900.16 KB)

1

AI-Pathway Companion consists of several health products and medical devices in their own right, and products under development. AI-Pathway Companion is not commercially available in all countries. Their future availability cannot be guaranteed.

2

All data is available as required per guideline. Feature dependent on quality of input data.

3

AI-Pathway Companion Lung Cancer VA10A supports Singlenprimary tumor. AI-Pathway Companion Lung Cancer VA10A supports Nonsmallncell Lung cancer cases only.

4

Dr. Mathias Prokop is employed by an institution that receives financial support from Siemens Healthineers for collaborations.

5

All data is available as required per guideline. Feature dependent on quality of input data. AI-Pathway Companion Lung Cancer VA10A supports NCCN guidelines. Customer shall ensure that guidelines are applicable and appropriate as per the local site policies and procedures and access to procedures.

Siemens Healthineers 2021

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide. Further information is available at www.siemens-healthineers.com.